Compare Johnson & Johnson (JNJ) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Workiva Inc — how do they compare? Johnson & Johnson trades at $261.49 (market cap $618.09B), while Workiva Inc trades at $73.32 (market cap $4.01B). The key difference: Johnson & Johnson is far larger — about 154.1× Workiva Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Workiva Inc for 21 Days on average.
| JNJ | WK | |
|---|---|---|
Market Cap | $618.09B | $4.01B |
Volume | 6,050,983 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $278.43 | $93.31 |
52-Week Low | $186.00 | $44.31 |
Typical Hold Time | 129 Days | 21 Days |
Enterprise Value | $646.37B | $3.99B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Workiva (WK) trades at $73.20, up 2.33% with bullish technical indicators and strong analyst support. The company shows improving fundamentals with revenue growth from $885M to $966M and a shift from a $26M loss to $47M profit in 2026. Recent product innovations in AI and regulatory platforms highlight business momentum, supported by consistent earnings beats in recent quarters.
Outlook remains positive with 89% analyst buy ratings and $86 consensus target offering 17% upside. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in regulatory technology. The stock's technical strength and fundamental improvement suggest continued growth potential, though investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
